Price Alert

Prothena Corporation (PRTA)

NASDAQ: PRTA · Real-Time Price · USD

9.92

-0.07 (-0.70%)

At close: Oct 03, 2025, 3:59 PM

9.73

-1.92%

After-hours: Oct 03, 2025, 05:08 PM EDT

-0.70% (1D)

Bid	9.2
Market Cap	533.99M
Revenue (ttm)	10.34M
Net Income (ttm)	-302.92M
EPS (ttm)	-5.62
PE Ratio (ttm)	-1.77
Forward PE	66.6
Analyst	Hold
Dividends	n/a

Ask	10.19
Volume	833,117
Avg. Volume (20D)	927,352
Open	10.02
Previous Close	9.99
Day's Range	9.58 - 10.16
52-Week Range	4.32 - 18.88
Beta	-0.12
Ex-Dividend Date	n/a

About PRTA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRTA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PRTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Prothena Corporation is scheduled to release its earnings on Nov 11, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+2.51%

PRTA stock has given up its prior loss. Prothena s... Unlock content with Pro Subscription

1 month ago

+2.51%

Prothena shares are trading lower after the company reported Phase 1 results for PRX012.

News

4 days ago · businesswire.com

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.

3 weeks ago · zacks.com

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

1 month ago · zacks.com

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

1 month ago · businesswire.com

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

2 months ago · fool.com

Prothena Q2 Revenue Drops 97%

Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker...

2 months ago · zacks.com

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.

2 months ago · businesswire.com

Prothena to Report Second Quarter 2025 Financial Results on August 4

DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

3 months ago · zacks.com

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.